Issue 21, 2020

Repurposing of the anti-HIV drug emtricitabine as a hydrogen-bonded cleft for bipyridines via cocrystallization

Abstract

We report supramolecular repurposing of emtricitabine (FTC, trade name: Emtriva®), a blockbuster FDA-approved anti-HIV agent. FTC is revealed to act as a hydrogen-bonded cleft for bipyridine recognition. The supramolecular repurposing is realized by the generation of four cocrystals through liquid-assisted grinding. The clefts comprise discrete three-component assemblies sustained by a combination of hydrogen bonds and π⋯π interactions.

Graphical abstract: Repurposing of the anti-HIV drug emtricitabine as a hydrogen-bonded cleft for bipyridines via cocrystallization

Supplementary files

Article information

Article type
Communication
Submitted
28 mar 2020
Accepted
06 may 2020
First published
06 may 2020

CrystEngComm, 2020,22, 3563-3566

Author version available

Repurposing of the anti-HIV drug emtricitabine as a hydrogen-bonded cleft for bipyridines via cocrystallization

G. Campillo-Alvarado, E. A. Keene, D. C. Swenson and L. R. MacGillivray, CrystEngComm, 2020, 22, 3563 DOI: 10.1039/D0CE00474J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements